Abstract
To evaluate the feasibility of adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) in Japanese patients with melanoma who failed immune-checkpoint inhibitor therapy, an open-label, single-arm, pilot study was conducted. We investigated the immunological and genetic factors of the pretreatment tumor and expanded TILs that may be associated with the clinical response. The treatment protocol comprised preparation of TIL culture, lympho-depleting non-myeloablative preconditioning with cyclophosphamide and fludarabine, TIL infusion, and intravenous administration of low-dose IL-2. Three patients of clinical subtypes mucosal, superficial spreading, and acral melanoma underwent TIL-ACT. Most severe adverse events, including fever and leukopenia, were manageable with the supportive regimen specified in the protocol, suggesting that the TIL-ACT regimen is suitable for Japanese patients with melanoma. One patient showed a short-term partial response, one relatively long-stable disease, and one experienced disease progression. Whole-exome and transcriptional sequencing of isolated tumor cells and immunohistochemical analyses before TIL-ACT revealed various immunostimulatory factors, including a high tu...Continue Reading
References
Dec 1, 1988·The Journal of Experimental Medicine·Y KawakamiM T Lotze
Sep 19, 1986·Science·S A RosenbergR Lafreniere
Sep 21, 2002·Science·Mark E DudleySteven A Rosenberg
Jun 28, 2006·The Journal of Experimental Medicine·Hidetoshi SumimotoYutaka Kawakami
Jan 7, 2010·PloS One·Juliette DesfrançoisNadine Gervois
Apr 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven A RosenbergMark E Dudley
Mar 29, 2012·The Cancer Journal·Richard WuLaszlo G Radvanyi
Sep 22, 2012·Journal of Immunotherapy·Shari Pilon-ThomasAmod A Sarnaik
Oct 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laszlo G RadvanyiPatrick Hwu
Apr 23, 2013·Trends in Immunology·Sarah Q CromePamela S Ohashi
May 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michal J BesserJacob Schachter
Feb 11, 2014·Journal of Immunotherapy·Shoko NakamuraYutaka Kawakami
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
Jan 1, 2012·ISRN Molecular Biology·Jean-Jacques Lebrun
Oct 21, 2016·Cancer·Alexander N ShoushtariMichael A Postow
May 4, 2017·Nature·Nicholas K HaywardGraham J Mann
May 10, 2017·Cancer Cell·Stefani SprangerThomas F Gajewski
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Nov 25, 2017·Nature Communications·Martin LaussGöran Jönsson
Oct 5, 2018·JCI Insight·Akio OsaAtsushi Kumanogoh
Oct 5, 2018·Journal for Immunotherapy of Cancer·Maartje W RohaanJohn B A G Haanen
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U DafniG Coukos
Aug 17, 2020·IScience·Hong Kwan KimJhingook Kim